H.C. Wainwright Reaffirms Their Buy Rating on Adamis Pharma


In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP), with a price target of $7. The company’s shares closed on Friday at $3.80.

Kolbert said:

“We assume that the expenses will moderate as R&D programs like Naloxone and the pediatric formulation of Symjepi are filed. The company ended the period with $10M in cash. The key issue of partnership timing remains.”

According to TipRanks.com, Kolbert has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.9% and a 38.1% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Sonoma Pharmaceuticals Inc, and Cellular Biomedicine Group.

Currently, the analyst consensus on Adamis Pharma is Strong Buy and the average price target is $7.41, representing a 95.0% upside.

In a report issued on May 11, Maxim Group also maintained a Buy rating on the stock with a $10 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.45 and a one-year low of $2.35. Currently, Adamis Pharma has an average volume of 692.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamis Pharmaceuticals Corp. is a biopharmaceutical company engages in the provision of medical development. Its activities include the combination of pharmaceuticals and biotechnology to produce medicines for patients, and physicians. It focuses on products such as inhaler technology in the field of allergy and respiratory diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts